All Interventions

    Peptide Therapy

    Hormones
    Peptide Hormones

    Therapeutic use of bioactive peptides to optimize hormones, enhance healing, modulate immunity, and support longevity.

    Evidence Summary

    6
    / 10Score
    Moderate
    Moderate Evidence

    Peptide therapy spans a wide evidence spectrum. The most rigorously studied therapeutic peptide is tesamorelin, an FDA-approved growth-hormone-releasing hormone (GHRH) analogue. A 2026 random-effects meta-analysis of five randomized controlled trials (Obesity Research & Clinical Practice) found that, versus placebo, tesamorelin reduced visceral adipose tissue by 27.71 cm2 (95% CI -38.37 to -17.06), lowered hepatic (liver) fat by 4.28 percentage points (95% CI -6.31 to -2.24) and trunk fat by 1.18 kg, while increasing lean body mass by 1.42 kg (95% CI 1.13 to 1.71) — a favorable body-composition shift — without serious adverse events or disruption of glucose control. These findings build on two pivotal 806-patient phase 3 trials (J Clin Endocrinol Metab, 2010) showing roughly a 15% reduction in visceral fat at 26 weeks that was maintained to 52 weeks, alongside about a 108 ng/mL rise in IGF-1 and improved triglycerides; subsequent analyses linked visceral-fat reduction to improved liver enzymes and metabolic markers. Importantly, this high-quality evidence comes from a specific approved indication (HIV-associated lipodystrophy); use for general longevity or body-composition goals is off-label and investigational. Many popular compounded peptides — including BPC-157 and TB-500 — have encouraging preclinical (mostly animal) data but little or no rigorous human trial evidence, and their regulatory and manufacturing status remains in flux. Source quality and physician supervision are essential. Educational information, not medical advice.

    Evidence Scale

    1
    2
    3
    4
    5
    6
    7
    8
    9
    10
    AnecdotalStrong RCT

    Mechanism of Action

    Therapeutic peptides are short amino-acid chains that act as signaling molecules — as secretagogues, growth factors, or modulators of inflammation and repair. Growth-hormone-axis peptides such as tesamorelin (a GHRH analogue) and GHRH/GHRP combinations stimulate the pituitary to release growth hormone in a more pulsatile, physiologic pattern, raising IGF-1 and preferentially mobilizing visceral fat while supporting lean mass. Other peptides are proposed to promote tissue repair, immune modulation, or metabolic signaling, though rigorous human evidence for many of these remains limited.

    Who Is This For?

    Tissue healing, GH optimization, cognitive enhancement, immune modulation. Individual peptide indications vary.

    Protocol & Dosing

    Dose

    Varies by peptide. BPC-157: 250-500mcg daily. CJC/Ipamorelin: 100-300mcg each.

    Frequency

    Daily to 5 days/week

    Duration

    Cycles of 4-12 weeks

    Protocol Summary

    Administration varies by peptide (subcutaneous injection, oral, or nasal) and is typically cycled. Appropriate candidate selection, pharmacy-grade sourcing, baseline and follow-up labs (including IGF-1 where GH-axis peptides are used), and physician supervision are essential. Dosing and duration are peptide-specific.

    Latest Evidence

    2026: five-trial meta-analysis of tesamorelin, the best-evidenced peptide

    Peptide therapy covers a broad evidence spectrum, and the strongest data belong to tesamorelin — an FDA-approved growth-hormone-releasing hormone (GHRH) analogue. A 2026 random-effects meta-analysis pooling five randomized controlled trials found that, compared with placebo, tesamorelin reduced visceral adipose tissue by about 28 cm² and liver fat by about 4 percentage points while adding roughly 1.4 kg of lean body mass — losing harmful fat while preserving muscle, a pattern most weight-loss approaches do not achieve. Earlier 806-patient phase 3 trials showed a ~15% visceral-fat reduction sustained to one year, with higher IGF-1 and improved triglycerides, and no clinically meaningful change in glucose control.

    This high-quality evidence comes from one approved indication (HIV-associated lipodystrophy); use for general longevity or body composition is off-label and investigational. Many popular compounded peptides, such as BPC-157 and TB-500, have mostly preclinical (animal) data and limited human evidence, with an evolving regulatory and sourcing landscape. Pharmacy quality, candidacy screening, and physician supervision are essential. Educational information, not medical advice.

    2026 META-ANALYSIS · 5 RANDOMIZED TRIALS

    Tesamorelin vs placebo: body-composition change

    Pooled mean difference vs placebo (kg), 95% CI

    Fat reductionLean-mass gain
    Visceral fat
    −27.71 cm²
    vs placebo · p<0.001
    Liver fat
    −4.28 percentage points
    vs placebo · p<0.001
    Source: Badran et al., Obesity Research & Clinical Practice (2026) — random-effects meta-analysis of 5 RCTs of tesamorelin in HIV-associated lipodystrophy. Mean difference vs placebo.

    Key references: Tesamorelin in HIV-associated lipodystrophy: meta-analysis of 5 RCTs — Obes. Res. Clin. Pract. (2026) · Tesamorelin & visceral fat: pooled phase 3 trials (n=806) — J. Clin. Endocrinol. Metab. (2010) · Visceral-fat reduction & metabolic profile — Clin. Infect. Dis. (2012) · Visceral-fat reduction & improved liver enzymes — AIDS (2017)

    Interactions & Precautions

    Contraindications

    • Pregnancy
    • Active cancer (for growth-promoting peptides)
    • Individual peptide-specific contraindications

    Potential Risks

    • •Unregulated sources
    • •Limited human data for some
    • •Regulatory issues

    Potential Side Effects

    Injection site reactions
    Peptide-specific: water retention, flushing, hunger

    Practitioner Notes

    Clinical annotations from Dr. Goel

    Tesamorelin is the best-evidenced peptide, with randomized-trial data for visceral-fat reduction in its approved HIV-lipodystrophy indication; its GH-axis mechanism underlies broader interest, but non-approved use is investigational. GHRH/GHRP combinations (e.g., CJC-1295/ipamorelin) are used clinically for GH-axis support with more limited controlled data. For peptides such as BPC-157 and thymosin analogues, human evidence is sparse and sourcing/regulatory status varies — pharmacy quality, careful candidacy screening, baseline and follow-up labs (including IGF-1 for GH-axis peptides), and physician supervision are critical. Avoid growth-promoting peptides in active malignancy and pregnancy. Educational information, not medical advice.
    SG

    Dr. Sanjeev Goel

    Chief Medical Officer, Peak Human

    Cost & Access

    Cost Range

    $$

    Accessibility

    Specialty clinics

    Availability varies by location

    PHS
    671
    / 1000
    T3
    Longevity Operator

    Sample member

    Longevity Operator

    The Peak Human Score · PHS v1

    One number for your longevity journey.

    FICO for credit. PHS for longevity. Eight biological domains collapsed into one provable score — intuitive at a glance, rigorous underneath.

    • Metabolic
    • Hormonal
    • Cardiovascular
    • Brain / Cognitive
    • Sleep
    • Musculoskeletal
    • Gut
    • Immunity / Inflammation